DE69724761T2 - Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat - Google Patents

Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat Download PDF

Info

Publication number
DE69724761T2
DE69724761T2 DE69724761T DE69724761T DE69724761T2 DE 69724761 T2 DE69724761 T2 DE 69724761T2 DE 69724761 T DE69724761 T DE 69724761T DE 69724761 T DE69724761 T DE 69724761T DE 69724761 T2 DE69724761 T2 DE 69724761T2
Authority
DE
Germany
Prior art keywords
antibody
intact
lym
antibodies
mab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69724761T
Other languages
German (de)
English (en)
Other versions
DE69724761D1 (de
Inventor
A. Leslie KHAWLI
L. Alan EPSTEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Techniclone Inc
Original Assignee
Techniclone Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Techniclone Inc filed Critical Techniclone Inc
Application granted granted Critical
Publication of DE69724761D1 publication Critical patent/DE69724761D1/de
Publication of DE69724761T2 publication Critical patent/DE69724761T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69724761T 1996-01-11 1997-01-06 Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat Expired - Lifetime DE69724761T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58607596A 1996-01-11 1996-01-11
PCT/US1997/000307 WO1997025069A1 (en) 1996-01-11 1997-01-06 Antibodies with reduced net positive charge
US586075 2000-06-02

Publications (2)

Publication Number Publication Date
DE69724761D1 DE69724761D1 (de) 2003-10-16
DE69724761T2 true DE69724761T2 (de) 2004-08-05

Family

ID=24344206

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69724761T Expired - Lifetime DE69724761T2 (de) 1996-01-11 1997-01-06 Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat

Country Status (10)

Country Link
EP (1) EP0873139B1 (enExample)
JP (2) JP2000503301A (enExample)
KR (1) KR100485240B1 (enExample)
AT (1) ATE249243T1 (enExample)
AU (1) AU730388B2 (enExample)
CA (1) CA2242750C (enExample)
DE (1) DE69724761T2 (enExample)
ES (1) ES2206683T3 (enExample)
RU (1) RU2219949C2 (enExample)
WO (1) WO1997025069A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047903A1 (en) * 2003-11-07 2005-05-26 Upstate Usa. Inc. A method for generating antibody conjugates that preserves antigen recognition
WO2013184200A1 (en) * 2012-06-05 2013-12-12 Msm Protein Technologies Human monoclonal antibodies against human chemokine receptor ccr7
MX354303B (es) * 2012-07-04 2018-02-23 Hoffmann La Roche Anticuerpos de anti-biotina y metodos de uso.
SG11201407420RA (en) 2012-07-04 2015-02-27 Hoffmann La Roche Covalently linked antigen-antibody conjugates
EP2869837B1 (en) 2012-07-04 2016-09-14 F. Hoffmann-La Roche AG Anti-theophylline antibodies and methods of use
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
EP3089758B1 (en) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
WO1988007553A1 (fr) * 1987-03-26 1988-10-06 Teijin Limited Procede de preparation d'un complexe d'anticorps
EP0593452A1 (en) * 1989-11-30 1994-04-27 Mallinckrodt Medical, Inc. Method for preparing a metal-radionuclide-labelled protein
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
SE9100142L (sv) * 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
CA2134239C (en) * 1992-06-09 2004-11-23 Donald B. Axworthy Pretargeting methods and compounds
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
JPH0853499A (ja) * 1994-08-10 1996-02-27 Green Cross Corp:The キメラ抗体Ｆａｂ断片のオリゴマー体

Also Published As

Publication number Publication date
KR19990077198A (ko) 1999-10-25
EP0873139A1 (en) 1998-10-28
WO1997025069A1 (en) 1997-07-17
RU2219949C2 (ru) 2003-12-27
DE69724761D1 (de) 2003-10-16
JP2012131808A (ja) 2012-07-12
CA2242750A1 (en) 1997-07-17
AU1693997A (en) 1997-08-01
ATE249243T1 (de) 2003-09-15
JP2000503301A (ja) 2000-03-21
CA2242750C (en) 2007-03-27
ES2206683T3 (es) 2004-05-16
KR100485240B1 (ko) 2006-10-24
EP0873139B1 (en) 2003-09-10
AU730388B2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
DE69128791T2 (de) Modifizierte antikörper mit kontrollierter clearance-zeit
DE3781946T2 (de) Therapeutische oder radiodiagnostische substanz.
US5990286A (en) Antibodies with reduced net positive charge
DE69123235T2 (de) Biotinylierte monoklonale Antikörper, Avidin und Biotin für die Diagnose und Therapie
DE3239410C2 (enExample)
DE68906728T2 (de) Polyspezifische anti-leukocytenkonjugat zum aufspueren und behandeln infektioeser und entzuendlicher laesionen.
DE3586188T2 (de) Antikoerper-metallionen-komplexe.
DE69006337T2 (de) Chimärer Antikörper zur Erkennung und Therapie von infektiösen und entzündlichen Läsionen.
DE69315565T2 (de) Konjugate von biotin und deferoxamine für radio-immuntherapie und -immunbilderzeugung
DE69029184T2 (de) Hydrophile Derivate, diagnostische und therapeutische Anwendungen, diagnostische oder therapeutische Reagenziensätze und immunologische Reagenzien
DE3885987T2 (de) Modifizierte Antikörperkonjugate mit erhöhter Eliminationsrate.
DE69129594T2 (de) Ein bifunktioneller ligand des dtpa typs
DE69228802T2 (de) System zur verbesserten in-vivo aussonderung diagnostischer und/oder therapeutischer wirkstoffe durch extrakorporales entfernen der wirkstoffe
DE68911397T2 (de) Radiohalogenierte Verbindungen für Markierung von spezifischen Stellen.
EP0271806B2 (de) Verfahren zur Herstellung einer mit Technetium-99m-markierten organspezifischen Substanz
DE69535094T2 (de) Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie
JP2012131808A (ja) 減少した正味の正電荷を有する抗体
DE3889851T2 (de) Verfahren und Materialien zur Herstellung der Lösungen von metallmarkierten Antikörpern.
EP1387701B1 (de) Immunkonjugate aus eidotter-antikörpern (igy), deren konfektionierung und anwendung in diagnostik und therapie
DE3320560A1 (de) Metallchelat-konjugierte monoklonale antikoerper
DE69030545T2 (de) Aufspüren und Behandeln von Infektionen durch Verwendung von Immunokonjukaten
DE69026387T2 (de) Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten
DE69933788T2 (de) Radiokonjugation von internalizierungsantikörpern
WO1997025069A9 (en) Antibodies with reduced net positive charge
MXPA98005565A (en) Antibodies with positive reduced load

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition